ライフサイエンスコーパス: unresectable

1 roscopy and the probability that disease was unresectable.

2 Of these, 5 were unresectable.

3 identifying lesions that were endoscopically unresectable.

4 p invasion and 91 (4.3%) were endoscopically unresectable.

5 surgically and are considered endoscopically unresectable.

6 %) were considered unresectable (286 locally unresectable, 244 with distant metastasis).

7 rgically explored, 530 (49%) were considered unresectable (286 locally unresectable, 244 with distant

8 neoadjuvant therapy (61%), risk of becoming unresectable (57%), and tumor-related symptoms (52%).

9 ible in achieving local control of otherwise unresectable abdominal tumors.

10 rolled patients aged 20 years and older with unresectable advanced or recurrent oesophageal squamous

11 Patients with metastatic or unresectable (advanced) pheochromocytoma and paraganglio

12 Patients with advanced, unresectable, American Joint Committee on Cancer stage I

13 rinsic pontine glioma (DIPG) is a surgically unresectable and devasting tumour in children.

14 disease control for patients with GCTB with unresectable and resectable tumours.

15 nts and Methods Patients < 18 years old with unresectable and/or progressive therapy-naive PLGG were

16 ncer stage III LA/BR PDAC who were initially unresectable, as determined by staging computed tomograp

17 Most of these tumors are unresectable at diagnosis and minimally responsive to co

18 No patient developed unresectable BD-IPMN carcinoma during follow-up.

19 is best suitable for locally invasive tumors unresectable because of location and vascular involvemen

20 ree survival in patients with metastatic and unresectable BRAF(V600) melanoma.

21 ac and superior mesenteric artery are deemed unresectable by conventional surgical methods.

22 iopsy-confirmed HCC or ICC, determined to be unresectable by multidisciplinary review, with a Child-T

23 compared with those who had locally advanced unresectable cancers (14 vs 11 months; P < 0.001).

24 Thirty patients with unresectable chemorefractory CRLM were treated with resi

25 Fifteen patients with unresectable, chemorefractory liver metastases of any or

26 emerged as a valuable therapeutic option in unresectable, chemotherapy-refractory hepatic metastases

27 A limitation for the treatment of unresectable cholangiocarcinoma (CCA) is its poor respon

28 Twenty-nine patients with unresectable cholangiocarcinoma, including 11 men (mean

29 ents with previously untreated metastatic or unresectable clear-cell renal-cell carcinoma received or

30 CTR and persistently unresectable cohorts differed significantly in preoperat

31 or never should be resected in patients with unresectable colorectal cancer metastases must be questi

32 Forty-nine patients with unresectable colorectal liver metastases (CRLM) were inc

33 Evaluate conversion rate of patients with unresectable colorectal-liver metastasis to complete res

34 0 resection rates in patients with primarily unresectable CRLM as evidenced in a recent randomized co

35 first evidence that patients with primarily unresectable CRLM treated by ALPPS have not only low per

36 In patients with extensive unresectable CRLM, the majority of whom were previously

37 erapies will benefit patients with advanced, unresectable CRTC1-MAML2-positive MEC.

38 37; 95% CI: 1.15-1.63) but not in those with unresectable disease (HR: 1.07; 95% CI: 0.89-1.29).

39 l lymph nodes (n = 47), and locally advanced unresectable disease (n = 18), that is, 6-DL and 69-UDL.

40 apeutic laparotomy in 55.9% of patients with unresectable disease and 23.2% of overall GBC patients.

41 However, the accuracy in detecting unresectable disease and a DL in locally advanced tumors

42 e tumors; however, the accuracy in detecting unresectable disease and a DL were similar.

43 The accuracy of SL for detecting unresectable disease and DL was 55.9% (95/170) and 94.1%

44 o underwent laparotomy, an additional 75 had unresectable disease due to surface liver metastasis (n

45 For most sarcomas, locally advanced or unresectable disease is still treated with cytotoxic che

46 th using radiation to approximate surgery in unresectable disease is that the radiation dose required

47 te responders," and the remainder either had unresectable disease or were unfit for surgery.

48 Other metastatic and locally advanced unresectable disease qualified as undetectable lesions (

49 randomised, phase 3 trial, had metastatic or unresectable disease, Eastern Cooperative Oncology Group

50 however, for patients with advanced stage or unresectable disease, locoregional and systemic chemothe

51 In FNAs obtained from 17 patients with unresectable disease, we identified at least 1 driver ge

52 mains the primary approach for metastatic or unresectable disease.

53 systemic treatment exists for patients with unresectable disease.

54 41 patients but abandoned in nine because of unresectable disease.

55 been limited effective treatment options for unresectable disease.

56 C and pembrolizumab as primary treatment for unresectable disease.

57 (PDAC) present with symptomatic, surgically unresectable disease.

58 patients with liver malignancies considered unresectable due to an insufficient FLR who underwent AL

59 For unresectable early-stage HCCA, excellent long-term tumor

60 otherapy-naive adults (aged >=18 years) with unresectable epithelioid malignant pleural mesothelioma

61 el treatment strategies for deadly recurrent unresectable forms of this soft tumor subtype, but also

62 ion part of the study included patients with unresectable gastrointestinal stromal tumours.

63 f regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least

64 with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous ima

65 mor site resulting in efficient treatment of unresectable GIST.

66 ted, histologically confirmed, metastatic or unresectable GISTs.

67 ying invasive polyps that are endoscopically unresectable (have at least 1 risk factor for metastasis

68 hepatocellular carcinoma (HCC) are <50%, and unresectable HCC carries a dismal prognosis owing to its

69 cant therapeutic benefit of TACE plus RT for unresectable HCC compared with TACE alone.

70 We reviewed unresectable HCC patients treated with palliative RT in

71 Participants with unresectable HCC were included in the trial and underwen

72 (96 men, 20 women; mean age, 63 years) with unresectable HCC who underwent at least two chemoemboliz

73 It included 79 patients with unresectable HCC who were treated with TACE.

74 Inclusion criteria included unresectable HCC, a treatment naive status, an Eastern C

75 After IAT for unresectable HCC, patients can be stratified into signif

76 urrently considered a first-line therapy for unresectable HCC.

77 ld be recommended for suitable patients with unresectable HCC.

78 ession-free survival rates than sorafenib in unresectable HCC.

79 er TACE by using idarubicin-loaded beads for unresectable HCC.

80 n shown to improve survival in patients with unresectable HCC; it has also been successfully used as

81 All patients diagnosed with unresectable hCCA between 2004 and 2016, who were eligib

82 ally increases the survival of patients with unresectable hCCA.

83 ecome a real alternative in the treatment of unresectable hepatic cancers.

84 [SIRT]) is a valuable therapeutic option for unresectable hepatic metastases arising from primary col

85 Twelve patients with initially unresectable hepatoblastoma were enrolled in the study.

86 For the management of selected children with unresectable hepatoblastoma, an almost opposite strategy

87 vide a novel local therapy for patients with unresectable hepatoblastoma.

88 survival and tumor response in patients with unresectable hepatocellular carcinoma (HCC) treated with

89 on therapy (SIRT) is a valuable treatment in unresectable hepatocellular carcinoma (HCC).

90 mbolization (TACE) is used for palliation of unresectable hepatocellular carcinoma (HCC).

91 to compare survival of patients treated for unresectable hepatocellular carcinoma (uHCC) with (90)Y

92 han with atezolizumab alone in patients with unresectable hepatocellular carcinoma not previously tre

93 Study of Liver Diseases criteria) confirmed unresectable hepatocellular carcinoma that was not amena

94 standard of care for patients with advanced unresectable hepatocellular carcinoma, but the relation

95 ith bevacizumab (anti-VEGF) in patients with unresectable hepatocellular carcinoma.

96 transarterial chemoembolization regimen for unresectable hepatocellular carcinoma.

97 splant has emerged as a promising option for unresectable hilar cholangiocarcinoma (hCCA).

98 OLT in appropriately selected patients with unresectable ICCA demonstrated promising disease recurre

99 al can be achieved in selected patients with unresectable ICCA using a combination of OLT and neoadju

100 However, in the case of unresectable ICCA, data on outcomes after OLT are limite

101 nts being considered for transplantation for unresectable ICCA.

102 f liver transplant criteria for treatment of unresectable ICCA.

103 Malignant tumors are considered "unresectable" if they are adhere to vital structures or

104 ly with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (N

105 rolled and analyzed; inclusion criteria were unresectable IIIA/IIIB histologically confirmed NSCLC, K

106 atients with relapsed ALCL and metastatic or unresectable IMT highlight the importance of the ALK pat

107 th cytotoxic drugs is standard treatment for unresectable intermediate-stage hepatocellular carcinoma

108 neoadjuvant) versus patients presenting with unresectable lesions, for which chemotherapy is used to

109 one of the principal tools in management of unresectable liver malignancies, including colorectal li

110 0)Y-yttrium microsphere radioembolization of unresectable liver metastases from breast cancer.

111 emotherapy can be recommended for downsizing unresectable liver metastases, but not for resectable le

112 For unresectable liver metastases, combination regimens resu

113 n excellent response rates for patients with unresectable liver metastasis from solid tumors.

114 LPPS procedure, aiming at removing primarily unresectable liver tumors, has been criticized for safet

115 on (TAE) has been extensively used to manage unresectable liver tumors.

116 who undergo yttrium 90 radioembolization for unresectable liver-dominant metastatic colorectal cancer

117 in 20 hospitals in the UK for patients with unresectable, liver-confined hepatocellular carcinoma.

118 LT is an effective treatment of unresectable LM from NET.

119 Isolated unresectable LMs are often the main determinant of overa

120 35% of patients with pancreatic cancer have unresectable locally advanced disease at diagnosis.

121 igned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mu

122 Patients aged at least 18 years with unresectable locally advanced or metastatic colorectal c

123 g efficacy and moderate survival duration in unresectable locally advanced or metastatic esthesioneur

124 We recruited adults (aged >/=18 years) with unresectable locally advanced or metastatic gastric or g

125 We recruited patients (>/=18 years old) with unresectable locally advanced or metastatic gastric or o

126 ulticohort study that includes patients with unresectable locally advanced or metastatic urothelial c

127 logical evidence of metastatic or surgically unresectable locally advanced sarcoma, had received up t

128 years or older with metastatic or surgically unresectable locally advanced urothelial carcinoma, meas

129 A 52-year-old man has unresectable locally recurrent melanoma of the left foot

130 en aged 18 years or older with HER2-positive unresectable, locally advanced or metastatic breast canc

131 lizumab plus nab-paclitaxel in patients with unresectable, locally advanced or metastatic triple-nega

132 d, phase 3 trial in patients with untreated, unresectable, locally advanced or metastatic urothelial

133 8 years or older with histologically proven, unresectable, locally advanced or metastatic, HER2-posit

134 number of previous chemotherapy regimens for unresectable, locally advanced, or metastatic disease (0

135 d for HER2-positive advanced gastric cancer (unresectable, locally advanced, or metastatic gastric ca

136 han drug' for the treatment of patients with unresectable, locally advanced, or metastatic medullary

137 e, HER2-positive advanced breast cancer with unresectable, locally advanced, recurrent or metastatic

138 This trend is exaggerated in unresectable, locally invasive or metastatic tumors, in

139 rial evaluated ramucirumab with docetaxel in unresectable, locally recurrent, or metastatic breast ca

140 d/or radiation) for incompletely resected or unresectable low-grade glioma (LGG).

141 ey met the following criteria: metastatic or unresectable lung cancer harbouring a RET rearrangement,

142 herapy with RF ablation after SPACE to treat unresectable lung tumors is technically feasible, safe,

143 emotherapy have efficacy in the treatment of unresectable malignant pleural mesothelioma (MPM).

144 latin combined with nintedanib or placebo in unresectable malignant pleural mesothelioma.

145 een resectable mesenteric lymph nodes versus unresectable masses in the root of the mesentery.

146 (RAF) kinase inhibitor vemurafenib to treat unresectable melanoma.

147 and Drug Administration for the treatment of unresectable melanoma.

148 In the subpopulation of patients with an unresectable meningioma and refractory to radiotherapy,

149 Patients with progressive unresectable meningioma were treated with (90)Y-DOTATOC

150 are promising tools for treating progressive unresectable meningioma, especially in cases of high tra

151 tolerated but had no impact on patients with unresectable meningioma.

152 the role of mifepristone in the treatment of unresectable meningioma.

153 ere 95% for resectable tumors versus 78% for unresectable mesenteric tumors (P = .02).

154 Outcomes for OS presenting with unresectable metastases or recurrent disease, or in thos

155 Unresectable metastatic bone sarcoma and soft-tissue sar

156 view the landscape of systemic therapies for unresectable metastatic colorectal cancer during the cur

157 overall survival of patients diagnosed with unresectable metastatic colorectal cancer has increased

158 FOLFOXIRI-Bev for the treatment of initially unresectable metastatic colorectal cancer in humans were

159 For patients with surgically unresectable metastatic colorectal cancer, FOLFOXIRI-Bev

160 c NET and 41 with nonpancreatic GEP NET) had unresectable metastatic disease graded as G1 or G2 (G1/G

161 tact primary tumor (IPT) and synchronous yet unresectable metastatic disease.

162 ession in up to 50% or more of patients with unresectable metastatic melanoma.

163 0 years and older with previously untreated, unresectable, metastatic colorectal cancer, who were not

164 18 years or older, had BRAF(V600E)-mutated, unresectable, metastatic, locally advanced, or recurrent

165 In the unresectable/metastatic setting, ipilimumab plus nivolum

166 In this retrospective study, patients with unresectable MHO were separated into the plastic stent (

167 trial in patients with previously untreated, unresectable MM.

168 nse rate by modified RECIST in patients with unresectable MPM.

169 In unresectable MRD, PNB nanosurgery improved survival twof

170 = 3) or exenteration (n = 11) or were judged unresectable (n = 13).

171 ficult to select treatment for patients with unresectable NETs because some patients can survive deca

172 improves survival in patients with stage III unresectable non-small-cell lung cancer when given as ma

173 cally or cytologically documented stage III, unresectable non-small-cell lung cancer, for which they

174 onsidered for the treatment of patients with unresectable nonmetastatic disease and for patients with

175 and Methods Chemotherapy-naive patients with unresectable, nonsarcomatoid MPM (Eastern Cooperative On

176 Concurrent chemotherapy and PBT to treat unresectable NSCLC afford promising clinical outcomes an

177 ive radiotherapy for patients with stage III unresectable NSCLC.

178 dependent prognostic factor in patients with unresectable oesophageal squamous cell carcinoma.

179 tis in patients treated with vemurafenib for unresectable or metastatic cutaneous melanoma.

180 be an effective treatment for patients with unresectable or metastatic DFSP, associated with respons

181 the current preferred agent for treatment of unresectable or metastatic DFSP.

182 and Drug Administration for the treatment of unresectable or metastatic melanoma in patients with Bra

183 D-1 mAbs for the treatment of BRAF-unmutated unresectable or metastatic melanoma is a landmark for th

184 untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were treated wit

185 Patients who have unresectable or metastatic melanoma with a BRAF V600E or

186 roximately one third of the patients who had unresectable or metastatic melanoma with a BRAF V600E or

187 ligible patients were 18 years or older, had unresectable or metastatic melanoma, and progressed afte

188 I studies and now approved for patients with unresectable or metastatic melanoma.

189 6) had previously untreated BRAF V600-mutant unresectable or metastatic melanoma.

190 placebo plus pembrolizumab in patients with unresectable or metastatic melanoma.

191 ab plus chemotherapy in the locally advanced unresectable or metastatic setting.

192 n plus olaratumab treatment in patients with unresectable or metastatic soft-tissue sarcoma at 16 cli

193 ars or older with a diagnosis of an advanced unresectable or metastatic soft-tissue sarcoma, of inter

194 neligible patients with locally advanced and unresectable or metastatic urothelial cancer.

195 they had pathologically confirmed, advanced (unresectable or metastatic), non-functional, well-differ

196 ult patients (aged >18 years) with advanced (unresectable or metastatic), well differentiated carcino

197 lly or cytologically confirmed advanced (ie, unresectable or metastatic, or both) incurable solid tum

198 tment options for patients with advanced-ie, unresectable or metastatic-melanoma.

199 rare, with limited therapeutic options when unresectable or metastatic; however, expression of somat

200 nts were eligible if their tumour was either unresectable or of low surgical curability on the basis

201 trial we enrolled patients with metastatic, unresectable, or locally advanced NSCLC from 121 sites i

202 cetaxel for patients with locally recurrent, unresectable, or metastatic HER2-positive breast cancer.

203 We included patients with locally advanced, unresectable, or metastatic high-grade soft-tissue sarco

204 with previously untreated locally advanced, unresectable, or metastatic soft-tissue sarcoma were scr

205 xorubicin in patients with locally advanced, unresectable, or metastatic soft-tissue sarcomas and so

206 e gene therapy of recurrent, metastatic, and unresectable ovarian cancer.

207 All 49 patients were deemed initially unresectable owing to vascular involvement.

208 compared with patients with locally advanced unresectable pancreatic adenocarcinoma.

209 For patients with locally advanced and unresectable pancreatic cancer (PDAC), neodadjuvant trea

210 nable ablative doses of cytotoxic therapy in unresectable pancreatic cancer by reducing untoward morb

211 Unresectable pancreatic cancer is almost universally let

212 data of consecutive patients with initially unresectable pancreatic cancer treated by neoadjuvant tr

213 s the first line treatment for patients with unresectable pancreatic cancer, however, insufficient dr

214 on therapy to GEM in patients with localized unresectable pancreatic cancer, with acceptable toxicity

215 and resection in 280 patients with initially unresectable pancreatic cancer-the largest single-center

216 ontrolled trials involving locally advanced, unresectable pancreatic cancer.

217 valuable option for patients with initially unresectable pancreatic NETs.

218 Patients with inoperable or unresectable pancreatic neuroendocrine tumors (NETs) hav

219 All patients had a borderline or unresectable pancreatic tumor (group 1) or oligometastat

220 Eleven of the 74 initially unresectable patients underwent conversion surgery for R

221 on therapy in patients with locally advanced unresectable PDA have reported mixed results, with effec

222 expansion, trial for patients with advanced, unresectable PDAC (n = 27), ATRA is re-purposed as a str

223 th borderline resectable or locally advanced unresectable PDAC receiving SOC neoadjuvant chemotherapy

224 cribed in detail for patients with initially unresectable PDAC undergoing resection after neoadjuvant

225 tion after neoadjuvant therapy for initially unresectable PDAC, preoperative CA 19-9 levels, lymph no

226 th borderline resectable or locally advanced unresectable PDAC.

227 th borderline resectable or locally advanced unresectable PDAC.

228 part of the study included patients with an unresectable PDGFRA D842V-mutant gastrointestinal stroma

229 We reviewed all patients with unresectable perihilar CCA treated with neoadjuvant chem

230 chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma caused the Uni

231 n age, 64.0 years; 10 women and 29 men) with unresectable pleural mesothelioma were treated with repe

232 esponse in the treatment of recurrent and/or unresectable pleural mesothelioma.

233 centres across 19 countries in patients with unresectable pleural or peritoneal malignant mesotheliom

234 a better outcome than patients with multiple unresectable PM (5-year OS, 88%, 92%, and 48%, respectiv

235 ients with histologically confirmed GIST and unresectable primary lesion or metastases undergoing an

236 well tolerated for patients with previously unresectable primary tumors and known metastatic disease

237 an 50% tumor resection at diagnosis, or with unresectable progressive disease after surgery alone.

238 vanced disease; 51 received chemotherapy for unresectable recurrent/metastatic disease.

239 ty as first-line treatment for metastatic or unresectable renal-cell carcinoma.

240 e consecutive adult patients with surgically unresectable single or multifocal measurable HCC and ade

241 cted database of patients undergoing IHP for unresectable solid tumor LM.

242 ntially offers more efficacious treatment of unresectable solid tumors without significant adverse si

243 tential to provide a theranostic solution to unresectable solid tumors.

244 microwave ablation (MWA) in the treatment of unresectable solitary hepatocellular carcinoma (HCC) up

245 Patients with treatment-naive, unresectable, solitary HCC </= 5 cm not amenable to RFA

246 nters with 42 patients who had inoperable or unresectable stage II to stage III NSCLC enrolled from N

247 andomized radiation dose-escalation trial in unresectable stage III non-small-cell lung cancer (NSCLC

248 was to compare the survival of patients with unresectable stage III non-small-cell lung cancer (NSCLC

249 ble-blind trial that recruited patients with unresectable stage III non-small-cell lung cancer who ha

250 e enrolled patients (aged >/= 18 years) with unresectable stage III non-small-cell lung cancer, a Zub

251 compared with placebo for all patients with unresectable stage III non-small-cell lung cancer.

252 rent chemotherapy and high-dose PBT to treat unresectable stage III NSCLC.

253 a In Solid Tumors version 1.1 (RECIST v1.1), unresectable stage III or IV melanoma (excluding ocular

254 Eligible patients (aged >/=18 years) with unresectable stage III or IV melanoma (treatment-naive o

255 18 years or older with previously untreated, unresectable stage III or IV melanoma and an Eastern Coo

256 rticipants were aged 18 years or older, with unresectable stage III or IV melanoma previously untreat

257 rvival and overall survival in patients with unresectable stage III or IV melanoma receiving epacados

258 atio, 945 previously untreated patients with unresectable stage III or IV melanoma to nivolumab alone

259 18 years or older with previously untreated, unresectable stage III or IV melanoma were randomly assi

260 In this phase I study, 90 patients with unresectable stage III or IV melanoma who were ipilimuma

261 il July 28, 2011, of patients (N = 245) with unresectable stage III or IV melanoma, at least 1 prior

262 Among patients with unresectable stage III or IV melanoma, treatment with ip

263 atients with untreated or previously treated unresectable stage III or IV melanoma, without previous

264 ials of nivolumab in 440 adult patients with unresectable stage III or stage IV melanoma, who had bee

265 Methods: Seventy unresectable stage III-IV melanoma patients who underwen

266 ctively analyzed all patients with nonuveal, unresectable stage III/IV melanoma treated with single-a

267 isplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell

268 Patients with treatment-naive, unresectable stage IIIc or IV melanoma were randomly ass

269 cally confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma were random

270 ed 423 previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF

271 RAF Val600Glu or Val600Lys mutation-positive unresectable stage IIIC or stage IV melanoma.

272 Patients with unresectable stage IIIc-IV, BRAF(V600) mutation-positive

273 ction (PTR) is recommended for patients with unresectable stage IV colorectal cancer (CRC) who presen

274 compared for 44 514 patients diagnosed with unresectable stage IV CRC from January 1, 1988, through

275 ribution of PTR to survival in patients with unresectable stage IV CRC over the past two decades in t

276 Of the 44 514 patients with unresectable stage IV CRC, 27 931 (62.7%) had undergone

277 c, and other-cause survival of patients with unresectable stage IV CRC.

278 acebo, with similar safety, in patients with unresectable, stage III non-small-cell lung cancer.

279 udy, 418 patients with previously untreated, unresectable, stage III/IV, wild-type BRAF melanoma were

280 lly confirmed, BRAF(V600) mutation-positive, unresectable, stage IIIC or IV melanoma.

281 Methods Patients with unresectable stages IIIB to IV melanoma, with no more th

282 lation included 185 Australian patients with unresectable stages IIIC and IV melanoma referred from C

283 When administered to a patient with unresectable symptomatic suprasellar hemangioblastoma, o

284 those patients who are at risk for having an unresectable tumor and who should be referred to a liver

285 while the seeds for recurrence reside in the unresectable tumor edge.

286 utic strategy for management of symptomatic, unresectable tumors by somatostatin analogue therapy.

287 In the cases of unresectable tumors embolization is used as a palliative

288 gnancy by imaging analysis for patients with unresectable tumors or who underwent neoadjuvant treatme

289 eatment modality that can selectively target unresectable tumors through optical activation of cytoto

290 e therapies is either to allow patients with unresectable tumors to become surgical candidates, provi

291 is demonstrating utility in the treatment of unresectable tumors where thermal ablation techniques ar

292 lected group of patients with conventionally unresectable tumors, ex vivo surgery can offer effective

293 sectable tumors and was 25% in patients with unresectable tumors.

294 survival benefit over locally advanced (LA) unresectable tumors.

295 a chance at R0 resection for conventionally unresectable tumors.

296 atients with chemotherapy-naive, metastatic, unresectable uLMS were randomly assigned to gemcitabine-

297 ty in patients with metastatic or surgically unresectable urothelial carcinoma whose disease progress

298 eated patients with metastatic or surgically unresectable urothelial carcinoma.

299 Surgically unresectable VHL-HBs or those in frail patients are chal

300 ty to a definitive answer (ie, resectable or unresectable) when the reports were structured than when